This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Udemy, Inc. (UDMY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
UDMYNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
What's in the Cards for Viatris Stock This Q4 Earnings?
by Zacks Equity Research
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
PCRXNegative Net Change VKTXNegative Net Change MIRMNegative Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Prothena Q4 Earnings Miss Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a wider-than-expected fourth-quarter loss. However, it reports encouraging pipeline progress for the quarter.
RHHBYPositive Net Change BMYNegative Net Change NVOPositive Net Change PRTAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
4 Seniors & Aging Demographics Stocks to Watch Right Now
by Urmimala Biswas
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
ABTNegative Net Change AMGNPositive Net Change MDTNegative Net Change SYKNegative Net Change DXCMNo Net Change ABBVPositive Net Change
artificial-intelligence biotechnology biotechs medical medical-devices oncology-screening pharmaceuticals
Cassava Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On SAVA's fourth-quarter 2024 earnings call, investors can expect updates regarding the company's pipeline developmental plans amid recent setbacks.
PCRXNegative Net Change ARGXPositive Net Change SAVAPositive Net Change MIRMNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bausch Health Beats on Q4 Earnings and Revenues, Xifaxan Boosts Sales
by Zacks Equity Research
BHC's fourth-quarter adjusted earnings and revenues beat estimates driven by Xifaxan. The guidance for 2025 is positive.
PCRXNegative Net Change BHCPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy 89BIO (ETNB) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ETNBNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Precigen, Inc. (PGEN) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PGENNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Lionsgate Studios Corp. (LION)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
LIONPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
by Zacks Equity Research
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
BMRNNegative Net Change FOLDNegative Net Change KRYSPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
PCRXNegative Net Change ADMANegative Net Change VKTXNegative Net Change MIRMNegative Net Change
biotechnology biotechs immuno-therapy medical pharmaceuticals
Biotech Stock Roundup: MRNA's Q4 Results, GILD's Update & Other News
by Zacks Equity Research
MRNA and GILD are in the spotlight this week on fourth-quarter earnings release and regulatory update, respectively.
GILDNegative Net Change MRNANegative Net Change SLDBNegative Net Change SEPNNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
by Urmimala Biswas
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
NVDAPositive Net Change ILMNNegative Net Change DXCMNo Net Change IQVNegative Net Change
artificial-intelligence biotechnology cloud-computing genomics medical
Exelixis Gains 6.7% Post Q4 Earnings: Is This the Right Time to Buy?
by Ekta Bagri
EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for further growth.
BMYNegative Net Change MRKPositive Net Change EXELNegative Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
by Ahan Chakraborty
RXRX is expected to provide updates on its oncology and rare disease pipeline in its fourth-quarter earnings release, given the absence of a marketed product.
JNJPositive Net Change PFENegative Net Change MRKPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings-preview medical oncology-screening pharmaceuticals
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
by Ekta Bagri
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive. We believe there is more room for growth and recommend the stock to investors.
GSKPositive Net Change MRKPositive Net Change GILDNegative Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
by Ahan Chakraborty
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
BMRNNegative Net Change HALOPositive Net Change FOLDNegative Net Change INSMPositive Net Change AXSMNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline
by Zacks Equity Research
Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the announcement.
ALNYPositive Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Portillo's Inc. (PTLO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PTLONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y
by Zacks Equity Research
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
REGNPositive Net Change ALNYPositive Net Change BMRNNegative Net Change RAREPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y
by Zacks Equity Research
ALNY reports better-than-expected fourth-quarter results as both earnings and revenues beat estimates driven by higher product sales.
REGNPositive Net Change ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
by Zacks Equity Research
GILD and BIIB are in the spotlight this week on fourth-quarter earnings release and outlook for 2025.
BIIBNegative Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Down Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
ZTS stock falls despite better-than-expected fourth-quarter results due to a weak 2025 outlook.
ALNYPositive Net Change BMRNNegative Net Change ZTSPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
New Strong Buy Stocks for February 13th
by Zacks Equity Research
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
FISINegative Net Change SYFPositive Net Change VCYTNegative Net Change SSBNegative Net Change DAWNPositive Net Change
biotechnology finance medical
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in Focus
by Zacks Equity Research
Exelixis beats on Q4 earnings and sales as lead drug Cabometyx maintains momentum. The company reiterates its guidance for 2025.
ALNYPositive Net Change MRKPositive Net Change EXELNegative Net Change IMCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals